Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Susan Pandya_2024
VIEWPOINTS

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Shots:  In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile  While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma  With a fast-track designation and breakthrough therapy…
March 7, 2024

Read more

Insights+: EMA Marketing Authorization of New Drugs in December 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots:  The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industry In December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis   PharmaShots has compiled a list of a…
January 23, 2024

Read more

VIEWPOINTS_Jennifer Davidson_2023
VIEWPOINTS

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Shots:  Jennifer Davidson, VP, of Medical Affairs Immunology, Johnson & Johnson Innovative Medicine shares insights from the data of the Phase III QUASAR induction study presented at the DDW'23  P-III QUASAR induction study 1 demonstrated positive results in patients who received TREMFYA 200 mg vs Placebo, with most of the patients achieving remission at week…
November 13, 2023

Read more

Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science
VIEWPOINTS

Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science

Shots: Leonard spoke about how Lilly is advancing in the field of metabolic disease research (esp. diabetes) He also talked about its lead candidate in type 2 diabetes and also discussed its clinical results in detail The interview summarizes Lilly’s objective to advance new discoveries and redefine diabetes care Smriti: Tell us how Lilly is leading…
August 16, 2022

Read more

PharmaShots Interview Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology
VIEWPOINTS

PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology

Shots: Daphne talked about the P-III study evaluating the safety and efficacy of Tremfya in people of color living with moderate to severe plaque psoriasis Daphne also spoke about how this clinical study will contribute to fill the gaps in care of people who are devoid of treatment due to racial and ethnic variations The…
July 26, 2022

Read more

PharmaShots Interview Dr. Bassem Maximos Shares Insights from New Research on Evofem’s Non-Hormonal Contraceptive Gel, P-III (AMPOWER) Study
VIEWPOINTS

PharmaShots Interview: Dr. Bassem Maximos Shares Insights from New Research on Evofem’s Non-Hormonal Contraceptive Gel, P-III (AMPOWER) Study

Shots: Bassem spoke about the new data presented in a poster presentation  at the ACOG annual meeting The data was based on the P-III (AMPOWER) study, which evaluates Evofem’s nonhormonal contraceptive gel to prevent pregnancy The interview gives an understanding of how Evofem is developing innovative products to improve women's health  Smriti: Please highlight the study…
July 13, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction data Shots: The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up period The…
March 15, 2022

Read more

PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
VIEWPOINTS

PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgery Shots: The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 2022

Read more

Viewpoints_Avanish Vellanki
VIEWPOINTS

PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma

In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company's lead candidate, RAIN-32. Shots: The company initiates P-III MANTRA trial to evaluate safety & efficacy of…
August 23, 2021

Read more